Market Overview

Recap: Veru Q2 Earnings


Shares of Veru (NASDAQ:VERU) rose 7% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 83.33% over the past year to ($0.01), which beat the estimate of ($0.04).

Revenue of $9,943,000 rose by 42.53% year over year, which missed the estimate of $10,970,000.

Looking Ahead

Veru hasn't issued any earnings guidance for the time being.

Veru hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 13, 2020

Time: 06:49 PM ET

Webcast URL:

Price Action

52-week high: $4.74

52-week low: $1.50

Price action over last quarter: down 16.05%

Company Overview

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.


Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at